Sari

The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)

Researchers are conducting a randomized, controlled, outcome assessor blind pilot study to evaluate the effectiveness of different ticagrelor dosing strategies combined with aspirin in preventing recurrence of non-disabling non-cardioembolic ischemic stroke or high risk transient ischemic attack (TIA) within 12 months. This study involves 100 patients diagnosed with ischemic stroke admitted to Bou-Ali Sina Hospital in Sari, Iran. The main goal is to compare the efficacy of de-escalation therapy using ticagrelor plus aspirin over varying durations and doses. Participants are randomly assigned to one of two groups. The control group receives aspirin 325 mg and ticagrelor 180 mg initially, followed by aspirin 80 mg daily and ticagrelor 90 mg twice daily for one month, then continuing with aspirin alone. The intervention group receives the same initial treatment but then continues with ticagrelor 60 mg twice daily plus aspirin 80 mg daily until month six, followed by aspirin alone. This approach aims to assess whether lowering the ticagrelor dose after one month reduces stroke recurrence while maintaining safety. During the 12-month follow-up, patients have four scheduled visits at 1, 3, 6, and 12 months with neurologists or neurology residents. Clinical data including NIH Stroke Scale and modified Rankin Scale scores are collected. Researchers monitor stroke recurrence confirmed by brain imaging, cardiovascular events, and major bleeding events following standardized criteria. The primary outcome is ischemic stroke recurrence at 12 months, with secondary outcomes including major hemorrhagic events, stroke recurrence at 6 months, and any cardiovascular events within the first year.

Warts caused by the human papillomavirus (HPV) are common among children, especially affecting school-aged kids and peaking in adolescence. These warts can cause pain, discomfort, and embarrassment, particularly when they appear on pressure points like the soles of the feet. Treating plantar warts is especially challenging, as many treatments can be painful and have high recurrence rates. This trial focuses on children aged 4 to 18 with palmar and plantar warts, aiming to evaluate a potential new treatment combination for effectiveness and side effects. The study compares a combination of topical 5% fluorouracil cream and 0.005% calcipotriol ointment applied twice daily for 21 days on the affected palmoplantar areas against matching placebos. Both the active treatments and placebos are provided in identical tubes to maintain blinding. This randomized, double-blind, placebo-controlled clinical trial investigates whether this combination offers a pain-free, effective alternative to current treatments. Participants will have the number of their warts recorded at 2, 4, and 8 weeks after starting treatment to assess response. The study involves monitoring for side effects and treatment adherence during this period. The trial includes children diagnosed by a dermatologist with up to 20 palmoplantar warts and excludes those with warts in other body areas, recent wart treatments, or immunodeficiency. The overall goal is to find a better treatment option for children suffering from these common warts.